Prospective trial of natalizumab personalized extended interval dosing by therapeutic drug monitoring in relapsing remitting multiple sclerosis (NEXT-MS)

Authors
Category Primary study
ConferenceMSmilan2023
Year 2023
This article has no abstract
Epistemonikos ID: 044f4de3b63acbace3c47a3b482bb69d97fdd1be
First added on: Jan 10, 2026